Ahead Of Alaska Summit, Russia Makes Biggest Advance In Ukraine In Over A Year
The Russian army took or claimed 110 square kilometres (42.5 square miles) on August 12 compared to the previous day. It was the most since late May 2024.
In recent months, Moscow has typically taken five or six days to progress at such a pace, although Russian advances have accelerated in recent weeks.
The US and Russian presidents, Donald Trump and Vladimir Putin, are to meet in Alaska on Friday.
Ukrainian President Volodymyr Zelensky acknowledged Tuesday that Russian troops had advanced by up to 10 kilometres (six miles) near the eastern coal mining town of Dobropillia, but that Kyiv would soon "destroy them."
Russia said Wednesday that it had taken two villages close to Dobropillia.
About 70 percent of Russia's advances in Ukraine so far this year are in the Donetsk region in eastern Ukraine, which the Kremlin claimed to have annexed in September 2022.
As of August 12, Moscow controlled or claimed to control 79 percent of the region, up from 62 percent a year ago.
The Russian army has also been attempting to seize the mining town of Pokrovsk for more than 18 months, following its capture of Bakhmut in May 2023.
The last two major cities held by Kyiv in the region are also at risk. They are Sloviansk and Kramatorsk, which is an important logistical hub for the front.
Russian progress in Ukraine has accelerated every month since April.
Between August 12, 2024 and August 12, 2025, the Russian army captured more than 6,100 square kilometres, four times more than the previous year, according to the AFP analysis of the institute's data.
However, these Russian advances account for less than 1 percent of pre-war Ukraine's territory, including Crimea and Donbass.
Russia currently has full or partial control over 19 per cent of Ukrainian territory.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
30 minutes ago
- Time of India
The New Delhi angle in the Putin-Trump summit
Even if US-Russia relations stabilise, it won't pry Moscow from Beijing. Even if it smoothens choppy geopolitical waters for India, the challenge of navigating between China, US, Russia will remain India-Russia ties have received a boost from an unlikely source. When Trump announced additional tariffs on import of Indian goods as 'punishment' for importing Russian crude oil, New Delhi rushed to reassure Moscow that it would not give in to White House pressure to abandon Russian energy imports. New Delhi then went a step further. It immediately signed a protocol on strategic industrial cooperation on aluminium, fertilisers, railways, and mining technology. Read the full story on TOI+. Facebook Twitter Linkedin Email Disclaimer Views expressed above are the author's own.
Hindustan Times
30 minutes ago
- Hindustan Times
Former Indian diplomat Vikas Swarup lauds India's stand amid Trump tariff hikes: ‘The bully will…'
Former diplomat Vikas Swarup has lauded India's firm stand in trade negotiations with the United States, saying the country has done the 'right thing' by resisting pressure from the Trump administration to open its agriculture and dairy sectors. Former diplomat Vikas Swarup praises India's firm stand in trade talks with the US, calling it the 'right thing".(X-@VikasSwarup) He said caving into a bully would only encourage the bully to increase demands, and yielding would invite even more pressure. His comments came after US President Donald Trump imposed a 50 per cent tariff on Indian goods in two phases, citing India's imports of Russian oil. In July, Trump had announced a 25 per cent tariff along with an unspecified penalty, despite hopes of an interim India-US trade deal that could have prevented higher duties. However, days later, he imposed another 25 per cent tariff, bringing the total to 50 per cent. Swarup described the tariff hikes as part of a broader 'pressure tactic to secure a more favourable deal.' The former diplomat also criticised Washington's deepening engagement with Pakistan, calling it a 'strategic mistake' given Islamabad's close ties with Beijing. 'I think it's a strategic mistake on the part of the US that you are getting in bed with Pakistan, which is in bed with China. China is the US's strategic competitor,' Swarup told news agency ANI. 'If you cave into a bully, then the bully will increase his demands. Then there will be even more demands. So, I think we have done the right thing. India is too large, too proud a country to become a camp follower of any other country. Our strategic autonomy has been the bedrock of our foreign policy right from the 1950s. I don't think that any Govt in Delhi can compromise on that,' he added. On Opposition criticism of India's foreign policy, Swarup maintained that the country must not yield to any pressure, saying that 'strategic autonomy is non-negotiable.'
India Today
30 minutes ago
- India Today
US pharma tariffs expected in weeks as Trump gears up for Alaska: Report
The announcement by President Donald Trump's administration of the results of a probe into pharmaceutical imports and new sector-specific US tariffs likely remains weeks away, four official and industry sources said, later than initially promised as he focusses on other Secretary Howard Lutnick had said in April when the review of whether reliance on foreign drug production threatens US national security was launched that he anticipated that it would conclude between mid-May and mid-June. Global pharmaceutical companies are bracing for the outcome of the investigation, which will usher in sector-specific tariffs that Trump has said could start small and eventually rise to 250%.advertisementThe Republican president said as recently as last week that his plan relies on phased-in tariffs, giving drugmakers time to increase manufacturing in the United States as he pushes to alter what he says are global trade distortions in many industries. One government official in Europe and a source with knowledge of the White House process, as well as two sources at European drug firms familiar with the process, told Reuters that the report and tariffs announcement were not imminent and likely weeks away. These sources spoke on condition of anonymity.A White House spokesperson, asked about media reporting indicating that the results of the probe could be several weeks away, cautioned that such reports were pure speculation unless confirmed by the White House. The spokesperson declined to give further details about the timing of the pharma probe or one involving investigation is examining pharmaceutical imports ranging from finished prescription drugs to active pharmaceutical ingredients, called APIs, and other raw materials, with the results to be disclosed in a Commerce Department said last month the tariff plan that will be based on the report would be completed by the end of July. Lutnick then said on July 29 it would be two more investigation was launched under Section 232 of the Trade Expansion Act of 1962. While the investigation is ongoing, the pharmaceutical sector has been exempted from the sweeping tariffs imposed by the Trump United States has reached bilateral trade deals with the UK, Japan, South Korea and the European Union that promised more favourable terms for their pharma exports than those expected to be levied on the sector globally.A European government official said that an announcement before the end of August appears unlikely but cautioned that the timeline could shift depending on other developments.A source at a European drugmaker said the Trump administration is focused on the US-Russia summit in Alaska on Friday and therefore no announcement is expected this source familiar with the White House process said that an announcement is unlikely to come this week given other source and one other source said that they expect the Trump administration to announce the results of its national security investigation into semiconductors first, followed by the pharma announcement, putting it a few weeks Section 232 provision authorises the president to adjust imports - including imposing tariffs - if a category of goods is being imported into the United States in quantities that "threaten or impair the national security."Medical goods historically have been spared from trade wars due to the potential harm to patient access, and drugmakers have said tariffs could undercut other health policy goals outlined by the Trump administration, including lowering drug tariffs on imported pharmaceutical products would mark the latest in a series of sectoral tariffs announced by the administration, following metals and cars, that some economists have predicted will drive up costs for American consumers.- EndsMust Watch
